These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 2730746)

  • 1. A naturalistic analytic study of veterans using naltrexone in Puerto Rico.
    Santos EF
    Bol Asoc Med P R; 1989 Apr; 81(4):134-6. PubMed ID: 2730746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.
    Mannelli P; Patkar AA; Peindl K; Murray HW; Wu LT; Hubbard R
    J Clin Psychopharmacol; 2007 Oct; 27(5):468-74. PubMed ID: 17873678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of the use of clonidine and naltrexone in the treatment of opioid addiction in the former USSR.
    Azatian A; Papiasvilli A; Joseph H
    J Addict Dis; 1994; 13(1):35-52. PubMed ID: 8018739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with naltrexone in suburban opioid addicts.
    Tennant FS; Rawson RA; Cohen AJ; Mann A
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):42-5. PubMed ID: 6469935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naltrexone induction: psychologic and pharmacologic strategies.
    Kleber HD; Kosten TR
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):29-38. PubMed ID: 6469934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does naltrexone affect craving in abstinent opioid-dependent patients?
    Dijkstra BA; De Jong CA; Bluschke SM; Krabbe PF; van der Staak CP
    Addict Biol; 2007 Jun; 12(2):176-82. PubMed ID: 17508990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retention and outcome in a narcotic antagonist treatment program.
    Capone T; Brahen L; Condren R; Kordal N; Melchionda R; Peterson M
    J Clin Psychol; 1986 Sep; 42(5):825-33. PubMed ID: 3760220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naltrexone: a clinical perspective.
    Greenstein RA; Arndt IC; McLellan AT; O'Brien CP; Evans B
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):25-8. PubMed ID: 6469933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?
    Nunes EV; Rothenberg JL; Sullivan MA; Carpenter KM; Kleber HD
    Am J Drug Alcohol Abuse; 2006; 32(4):503-17. PubMed ID: 17127538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the National Institute on Drug Abuse in the development of naltrexone.
    Ginzburg HM; Glass WJ
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):4-6. PubMed ID: 6088469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence.
    Carreño JE; Alvarez CE; Narciso GI; Bascarán MT; Díaz M; Bobes J
    Addict Biol; 2003 Dec; 8(4):429-38. PubMed ID: 14690879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How do elderly veterans who fail to keep outpatient clinic appointments differ from those who do not.
    López Martínez P; Algarín H; Beauchamp VE; Lugo C; Ortiz C; Vega M; Velázquez E; Zayas Y; Santiago A
    P R Health Sci J; 1987 Dec; 6(3):141-6. PubMed ID: 3438457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naltrexone treatment in a jail work-release program.
    Brahen LS; Henderson RK; Capone T; Kordal N
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):49-52. PubMed ID: 6469937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adolescent opioid abuse.
    O'Brien CP
    Arch Gen Psychiatry; 2005 Oct; 62(10):1165. PubMed ID: 16203962
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical use of naltrexone].
    Manzanares J
    Rev Med Univ Navarra; 1995; 40(2):78-84. PubMed ID: 7569550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of naltrexone to extinguish opioid-conditioned responses.
    O'Brien CP; Childress AR; McLellan AT; Ternes J; Ehrman RN
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):53-6. PubMed ID: 6381473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone in addicted business executives and physicians.
    Washton AM; Pottash AC; Gold MS
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):39-41. PubMed ID: 6088468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Problems in methadone treatment: the influence of reference groups.
    Hunt DE; Lipton DS; Goldsmith DS; Strug DL
    NIDA Res Monogr; 1984; 46():8-22. PubMed ID: 6427626
    [No Abstract]   [Full Text] [Related]  

  • 19. Strategies to improve compliance with narcotic antagonists.
    Kosten TR; Kleber HD
    Am J Drug Alcohol Abuse; 1984; 10(2):249-66. PubMed ID: 6475891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naltrexone in addicted physicians and business executives.
    Washton AM; Gold MS; Pottash AC
    NIDA Res Monogr; 1984; 55():185-90. PubMed ID: 6443377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.